Scottish Enterprise

uFraction8 provides scalable bioprocessing technology enabling biomass filtration, separation and dewatering, used with wide range of microbes like micro algae, yeast and bacteria, sorting biomass from culture medium with no harm and no flocculants unlike centrifuges, filters and membranes.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Neuranics is a company focused on developing advanced magnetic sensors integrated with semiconductor technology for applications in health, fitness, and the metaverse. Their proprietary technology is designed to detect minute magnetic impulses produced by the body's organs, utilizing scalable spintronics sensors. This innovative approach aims to address the limitations of current health monitoring devices and enhance human-machine interfaces. By leveraging magnetic sensing, Neuranics seeks to improve the interaction with the central, peripheral, and autonomic nervous systems, as well as muscles, thereby offering significant advancements for healthcare companies in creating next-generation wearable and implantable devices.

Invizius is a biotech company focused on enhancing extracorporeal treatments for patients, particularly in the areas of dialysis, cardiopulmonary bypass, and ECMO. The company has developed H-Guard, an advanced hemocompatible coating designed to mitigate foreign body reactions in the bloodstream. This innovative coating acts as an anti-inflammatory treatment that lines the inside of dialysis filters, allowing the process to occur without triggering the body's immune response. By suppressing unwanted innate immune reactions, Invizius aims to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis. The company's efforts are positioned to revolutionize the way dialysis and other extracorporeal treatments are administered, improving patient outcomes and overall treatment efficacy.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, specializing in the modulation of the innate immune system through the development of novel peptide therapeutics. Founded in 2012 and formerly known as Alfacyte Limited, the company focuses on creating hybrid interferons, which are innovative medicines that combine features from various natural interferon subtypes. These hybrid molecules aim to enhance therapeutic efficacy and improve safety across several high-value areas, including cancer, atopic dermatitis, psoriasis, and COVID-19. By advancing this new class of therapeutics, ILC Therapeutics seeks to improve patient outcomes and contribute to the treatment of challenging diseases.

Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.

ŌGI Bio is a newly formed start-up company from The University of Edinburgh with the mission to revolutionize the way that microbes are grown and managed.

Nebu-Flow is a manufacturer focused on developing advanced inhaled drug delivery systems for patients with respiratory disorders. The company specializes in innovative technology that controls droplet size to enhance deep lung deposition, facilitating effective drug delivery through inhalation. This technology not only targets existing formulations but also accommodates emerging therapeutics, including biologics, nanomedicines, and vaccines. By enabling injection-free systemic drug delivery, Nebu-Flow aims to improve treatment options for various respiratory, cardiovascular, and central nervous system conditions. The company is also dedicated to minimizing its environmental impact while ensuring its nebulizers remain user-friendly and high-performing.

Glen Clova Scientific is focused on developing a new generation of active biological drugs that aim to create natural antibodies against harmful targets. These innovative drugs are designed to improve the treatment of chronic diseases by minimizing the need for safety monitoring and reducing the frequency of dosing. As a result, patients benefit from a more cost-effective treatment approach, while the company also seeks to address healthcare challenges in markets with limited infrastructure.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Microplate Dx is a developer of diagnostic technology focused on reducing fatalities from drug-resistant infections. As an award-winning spinout from the University of Strathclyde in Glasgow, the company aims to address the global health challenge of antimicrobial resistance. Microplate Dx's innovative solutions utilize highly sensitive biosensor electrodes, combined with miniaturized hydrogel deposits containing antibiotics specific to the infection being detected. Their medical diagnostic device provides a low-cost and accurate point-of-care alternative, enabling rapid antibiotic prescribing in under one hour. This approach enhances antibiotic stewardship and strives to manage the spread of antimicrobial resistance effectively.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

BDD is a specialist drug formulation company providing expertise across all areas of drug delivery. We offer a full service package to fit individual needs from troubleshooting, formulation development, in vitro and in vivo testing. Our patented time release technology OralogiK provides unrivaled control of drug release at the right place and time. OralogiK has been validated in numerous clinical studies, enables the oral delivery of single, multi-dose or combination drugs at pre-determined times between one and 12 hours after being swallowed by the patient. This facilitates such benefits as: night time dosing of a drug to be delivered pre-wakeup multi-phased delivery of one or more drugs (immediate and delayed) to allow once-a-day dosing or for pre-treatment by one drug before the delivery of a second delivery of drugs to a specific regions of the digestive system (e.g. the colon) BDD also specialize in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Carbogenics Ltd is a company based in Edinburgh, United Kingdom, specializing in the development and production of sustainable fertilizers and bio-additives. Established in 2016, Carbogenics has created an innovative process that transforms disposable coffee cups and other non-recyclable paper waste into a carbon-rich material, known as CreChar. This product serves as a carbon additive that enhances biogas production in anaerobic digestion and improves plant growth, ultimately benefiting farmers by increasing crop yields and profitability. In addition to its product offerings, Carbogenics also provides consultancy and analytical services to operators in the anaerobic digestion and wastewater treatment sectors, addressing customer inquiries through various communication channels.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Causeway Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative microRNA therapies for musculoskeletal health. Founded in 2015, the company specializes in treating tendon injuries and disorders in both humans and horses. Its primary products include EquiMiR, designed to treat equine tendinopathy by mimicking natural microRNA with enhanced pharmacological properties, and TenoMiR, which aims to restore key microRNA levels to enhance tendon strength and aid recovery. By targeting the molecular mechanisms that lead to tendinopathy, Causeway Therapeutics seeks to provide effective solutions for managing pain and promoting healing in damaged tendons.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Green Bioactives is a company focused on sustainable biomanufacturing, specializing in the production of plant biomolecules through a cell-based platform. This innovative approach involves identifying, isolating, and cultivating plant vascular stem cells, allowing for the development of bioactive molecules suitable for various commercial applications. The company's technology aims to provide new solutions for the cosmetic, pharmaceutical, food, and agricultural sectors, addressing the global demand for efficient and sustainable food production. By leveraging natural plant biochemistry, Green Bioactives offers a reliable and economical alternative to traditional methods, promoting sustainability in multiple industries.

Roslin Technologies is an ag-tech and food tech company focused on advancing biotechnologies to enhance protein production. The company specializes in animal stem cells, having developed perpetually self-renewing, pluripotent stem cells that have the potential to revolutionize the cultivated meat market. By providing these innovative cell lines and associated media formulations, Roslin Technologies enables companies in the cultivated meat industry to reduce costs and accelerate their market entry. Additionally, the company leverages its expertise in genomic capabilities to explore cell therapies aimed at treating incurable diseases in animals. Through these efforts, Roslin Technologies is committed to transforming the future of protein production.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.

Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

ŌGI Bio is a newly formed start-up company from The University of Edinburgh with the mission to revolutionize the way that microbes are grown and managed.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. The company aims to block the action of the enzyme KMO, which plays a crucial role in regulating systemic inflammation and is implicated in various medical conditions. By providing new therapies that target this key enzyme, Kynos Therapeutics seeks to offer innovative treatments for conditions where there is a significant demand for effective medicines.

WellFish Tech is an aquaculture company headquartered in Bridge of Weir, United Kingdom, focused on enhancing fish health monitoring through rapid and non-lethal blood analysis. Founded in 2021 by Brian Quinn, the company aims to improve the sustainability and productivity of the aquaculture industry. WellFish Tech provides health monitoring services that assess fish stock in marine net pens, including smoltification, toxicity assessment, and aquafeed optimization. Their dynamic diagnostic platform is designed to adapt to the evolving needs of the growing aquaculture sector, enabling industrialists to reduce costs, increase productivity, and ultimately enhance profitability.

Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.

uFraction8 provides scalable bioprocessing technology enabling biomass filtration, separation and dewatering, used with wide range of microbes like micro algae, yeast and bacteria, sorting biomass from culture medium with no harm and no flocculants unlike centrifuges, filters and membranes.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Dyneval specializes in portable technology for the analysis of cattle semen quality. Its innovative system measures semen motility in conditions that closely mimic natural environments, providing valuable insights into sperm behavior. By utilizing dynescan data, Dyneval's technology assists in formulating breeding plans and verifying semen quality throughout the supply chain. This approach aims to enhance livestock production, thereby contributing to food security while also addressing environmental concerns by reducing methane emissions. Ultimately, Dyneval's solutions help farmers minimize losses associated with low conception rates.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, specializing in the modulation of the innate immune system through the development of novel peptide therapeutics. Founded in 2012 and formerly known as Alfacyte Limited, the company focuses on creating hybrid interferons, which are innovative medicines that combine features from various natural interferon subtypes. These hybrid molecules aim to enhance therapeutic efficacy and improve safety across several high-value areas, including cancer, atopic dermatitis, psoriasis, and COVID-19. By advancing this new class of therapeutics, ILC Therapeutics seeks to improve patient outcomes and contribute to the treatment of challenging diseases.

Invizius is a biotech company focused on enhancing extracorporeal treatments for patients, particularly in the areas of dialysis, cardiopulmonary bypass, and ECMO. The company has developed H-Guard, an advanced hemocompatible coating designed to mitigate foreign body reactions in the bloodstream. This innovative coating acts as an anti-inflammatory treatment that lines the inside of dialysis filters, allowing the process to occur without triggering the body's immune response. By suppressing unwanted innate immune reactions, Invizius aims to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis. The company's efforts are positioned to revolutionize the way dialysis and other extracorporeal treatments are administered, improving patient outcomes and overall treatment efficacy.

BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.

BDD is a specialist drug formulation company providing expertise across all areas of drug delivery. We offer a full service package to fit individual needs from troubleshooting, formulation development, in vitro and in vivo testing. Our patented time release technology OralogiK provides unrivaled control of drug release at the right place and time. OralogiK has been validated in numerous clinical studies, enables the oral delivery of single, multi-dose or combination drugs at pre-determined times between one and 12 hours after being swallowed by the patient. This facilitates such benefits as: night time dosing of a drug to be delivered pre-wakeup multi-phased delivery of one or more drugs (immediate and delayed) to allow once-a-day dosing or for pre-treatment by one drug before the delivery of a second delivery of drugs to a specific regions of the digestive system (e.g. the colon) BDD also specialize in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Asklepios BioPharmaceutical is a biotechnology company focused on developing adeno-associated virus (AAV) gene therapies for genetic disorders and rare diseases. The company utilizes proprietary AAV technology and has established comprehensive manufacturing capabilities, alongside a pipeline that includes clinical-stage programs targeting Pompe disease and congestive heart failure, as well as a preclinical portfolio addressing neuromuscular and central nervous system disorders. Additionally, Asklepios has out-licensed clinical indications for conditions such as hemophilia and Duchenne muscular dystrophy. Its gene therapy platform encompasses an advanced cell line manufacturing process and a diverse library of AAV capsids and promoters. Founded in 2001 and headquartered in Research Triangle Park, North Carolina, Asklepios BioPharmaceutical aims to enhance patient outcomes through innovative genetic medicine solutions.

Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Censo Bio is a specialist CRO with exceptional skill in complex cell biology, specializing in human neurodegenerative, neuroinflammatory, and inflammatory disease models.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.

Censo Bio is a specialist CRO with exceptional skill in complex cell biology, specializing in human neurodegenerative, neuroinflammatory, and inflammatory disease models.

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.

Invizius is a biotech company focused on enhancing extracorporeal treatments for patients, particularly in the areas of dialysis, cardiopulmonary bypass, and ECMO. The company has developed H-Guard, an advanced hemocompatible coating designed to mitigate foreign body reactions in the bloodstream. This innovative coating acts as an anti-inflammatory treatment that lines the inside of dialysis filters, allowing the process to occur without triggering the body's immune response. By suppressing unwanted innate immune reactions, Invizius aims to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis. The company's efforts are positioned to revolutionize the way dialysis and other extracorporeal treatments are administered, improving patient outcomes and overall treatment efficacy.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

CuanTec are a Scottish based blue biotech company making compostable, antimicrobial bioplastic from waste of the fisheries industry, providing an environmentally responsible alternative to polluting packaging. CuanTec are using a circular economy solution where waste from processing of the fisheries industry is put to good use. Cuantec extracts chitin from marine waste, langoustines caught in the pollution free waters of the North Atlantic. Our chitin is obtained biologically, thanks to harmless bacteria, in a low-energy process with minimal wastage, and at a high yield providing a very high-quality product. Our chitosan is obtained thanks to an innovative sustainable process, using less energy and 5 time less sodium hydroxide than the current chemical process.

Censo Bio is a specialist CRO with exceptional skill in complex cell biology, specializing in human neurodegenerative, neuroinflammatory, and inflammatory disease models.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Synpromics develops and commercializes synthetic promoters to control gene expressions and regulations. The company was founded in 2010 and is based in Edinburgh, United Kingdom.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

BDD is a specialist drug formulation company providing expertise across all areas of drug delivery. We offer a full service package to fit individual needs from troubleshooting, formulation development, in vitro and in vivo testing. Our patented time release technology OralogiK provides unrivaled control of drug release at the right place and time. OralogiK has been validated in numerous clinical studies, enables the oral delivery of single, multi-dose or combination drugs at pre-determined times between one and 12 hours after being swallowed by the patient. This facilitates such benefits as: night time dosing of a drug to be delivered pre-wakeup multi-phased delivery of one or more drugs (immediate and delayed) to allow once-a-day dosing or for pre-treatment by one drug before the delivery of a second delivery of drugs to a specific regions of the digestive system (e.g. the colon) BDD also specialize in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report.

Invizius is a biotech company focused on enhancing extracorporeal treatments for patients, particularly in the areas of dialysis, cardiopulmonary bypass, and ECMO. The company has developed H-Guard, an advanced hemocompatible coating designed to mitigate foreign body reactions in the bloodstream. This innovative coating acts as an anti-inflammatory treatment that lines the inside of dialysis filters, allowing the process to occur without triggering the body's immune response. By suppressing unwanted innate immune reactions, Invizius aims to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis. The company's efforts are positioned to revolutionize the way dialysis and other extracorporeal treatments are administered, improving patient outcomes and overall treatment efficacy.

Causeway Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative microRNA therapies for musculoskeletal health. Founded in 2015, the company specializes in treating tendon injuries and disorders in both humans and horses. Its primary products include EquiMiR, designed to treat equine tendinopathy by mimicking natural microRNA with enhanced pharmacological properties, and TenoMiR, which aims to restore key microRNA levels to enhance tendon strength and aid recovery. By targeting the molecular mechanisms that lead to tendinopathy, Causeway Therapeutics seeks to provide effective solutions for managing pain and promoting healing in damaged tendons.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

Ryboquin™ uses its expertise to turn under-developed intellectual property ideas into viable commercial realities. Founded in Scotland, Ryboquin Ltd is a privately held, virtual pharmaceutical company focused on commercialising patented technologies in the area of human cancer medicine. Founded in Scotland, Ryboquin is a privately held, virtual pharmaceutical company focused on commercializing patented technologies in the area of human cancer medicine.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

Synpromics develops and commercializes synthetic promoters to control gene expressions and regulations. The company was founded in 2010 and is based in Edinburgh, United Kingdom.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.

MOFgen Ltd is a pioneering company that specializes in the commercialization of metal-organic frameworks (MOFs) for medical and therapeutic applications. Originating as a spin-out from the University of St Andrews, the company leverages patented technology developed by renowned porous material scientist Prof Russell Morris. MOFgen focuses on designing, manufacturing, and formulating MOFs to create innovative solutions for healthcare challenges. Its products include powdery solids with microscopic pores capable of incorporating antibacterial agents, wound healing compounds, and anti-thrombotic substances. These advanced coatings for medical devices aim to enhance patient care by reducing infection rates and minimizing the need for prolonged hospital stays. Through collaboration with various partners, MOFgen is committed to developing tailored solutions for issues such as healthcare-associated infections, bacterial resistance, chronic wounds, and arterial access.

CuanTec are a Scottish based blue biotech company making compostable, antimicrobial bioplastic from waste of the fisheries industry, providing an environmentally responsible alternative to polluting packaging. CuanTec are using a circular economy solution where waste from processing of the fisheries industry is put to good use. Cuantec extracts chitin from marine waste, langoustines caught in the pollution free waters of the North Atlantic. Our chitin is obtained biologically, thanks to harmless bacteria, in a low-energy process with minimal wastage, and at a high yield providing a very high-quality product. Our chitosan is obtained thanks to an innovative sustainable process, using less energy and 5 time less sodium hydroxide than the current chemical process.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from waste streams in the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms and is suitable for a wide range of applications, including paints, coatings, paper, food products, personal care, home care, cosmetics, concrete, drilling fluids, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on creating sustainable, non-hydrocarbon-based materials that enhance product performance while also promoting cost savings for its clients.

Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, specializing in the development of self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010, the company focuses on a range of applications within spine, trauma, extremities, and biologics. Taragenyx creates innovative therapeutic implants, incorporating bio-passive, bio-active, and bio-regenerative coatings that integrate active pharmaceuticals and biologics into the implant surface. This technology allows for localized release of compounds post-operatively, which can accelerate bone growth, promote faster healing, and reduce the risk of infection and pain. The company’s products are specifically designed to address limb-threatening surgical complications, thereby improving patient outcomes in orthopedic and dental procedures.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development of tunable peptide hydrogels for various applications in cell culture research, including toxicity screening, cancer research, and potential therapeutic uses. Founded in 2012, the company provides hydrogels that mimic the physical and chemical properties of natural tissues, allowing researchers to grow and manipulate cells in a realistic three-dimensional environment. These products are designed to meet the specific requirements of different cell types, offering a viable alternative to traditional animal testing and other 3D cell culture methods. Biogelx's patented hydrogel technologies are marketed in the US, Europe, and Asia, catering to academic institutions, medical researchers, and pharmaceutical companies engaged in drug development and regenerative medicine.

i2eye diagnostics is a spin-out company from the University of Edinburgh and the Edinburgh BioQuarter.

Clyde Biosciences specializes in developmental drug testing, focusing on cardiac cell analysis solutions. The company offers a platform that generates human-relevant functional data from cardiomyocytes, which aids in understanding the mechanisms and actions of drugs in development. By providing insights into drug performance at earlier stages, Clyde Biosciences aims to reduce risks associated with the development of new medicines.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

Synpromics develops and commercializes synthetic promoters to control gene expressions and regulations. The company was founded in 2010 and is based in Edinburgh, United Kingdom.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from waste streams in the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms and is suitable for a wide range of applications, including paints, coatings, paper, food products, personal care, home care, cosmetics, concrete, drilling fluids, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on creating sustainable, non-hydrocarbon-based materials that enhance product performance while also promoting cost savings for its clients.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, primarily targeting the life science research community. Ubiquigent focuses on protein degradation and the ubiquitin signaling systems, providing services that support drug discovery efforts aimed at developing novel deubiquitylase (DUB) enzyme inhibitors. The company works closely with academic researchers and pharmaceutical scientists, aiding in the exploration of therapeutic applications for DUB modulators in areas with significant unmet medical needs. Ubiquigent is committed to generating intellectual property through its innovative drug discovery programs, which include optimizing compounds that target the ubiquitin cascade.

Fixed Phage was founded with the aim of developing new products for various industries from our platform technology. Each of our core technologies is comprehensively described and protected by our IP portfolio. We work at our custom designed laboratory and support infrastructure facilities located at the prestigious West of Scotland Science Park. Our in-house abilities include all work required to identify, manufacture and work with bacteriophage. Fixed Phage continually invests in innovation and our team presents at conferences and exhibitions around the world. To learn about whether we will be presenting near you, please follow us on social media.

Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, specializing in the development of self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010, the company focuses on a range of applications within spine, trauma, extremities, and biologics. Taragenyx creates innovative therapeutic implants, incorporating bio-passive, bio-active, and bio-regenerative coatings that integrate active pharmaceuticals and biologics into the implant surface. This technology allows for localized release of compounds post-operatively, which can accelerate bone growth, promote faster healing, and reduce the risk of infection and pain. The company’s products are specifically designed to address limb-threatening surgical complications, thereby improving patient outcomes in orthopedic and dental procedures.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development of tunable peptide hydrogels for various applications in cell culture research, including toxicity screening, cancer research, and potential therapeutic uses. Founded in 2012, the company provides hydrogels that mimic the physical and chemical properties of natural tissues, allowing researchers to grow and manipulate cells in a realistic three-dimensional environment. These products are designed to meet the specific requirements of different cell types, offering a viable alternative to traditional animal testing and other 3D cell culture methods. Biogelx's patented hydrogel technologies are marketed in the US, Europe, and Asia, catering to academic institutions, medical researchers, and pharmaceutical companies engaged in drug development and regenerative medicine.

Touch Bionics Inc., is a Livingston, Scotland, UK-based developer of advanced upper-limb prosthetics.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.

Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.

CXR Biosciences Limited specializes in preclinical services, focusing on investigative and mechanistic toxicology, as well as metabolic and pharmacokinetics/toxicokinetics. The company evaluates human hazard and risk, offering solutions for chemical design, candidate selection, and translational risk assessment. CXR generates critical data for PK/TK and metabolic profiling, assisting clients in addressing safety concerns related to drug and chemical candidates. Its technological capabilities include in vivo and in vitro analyses, analytical techniques, microarrays, and toxicogenomics, among others. CXR serves a diverse range of sectors, including pharmaceuticals, agrochemicals, biotechnology, and consumer products. Founded in 2000 and based in Dundee, United Kingdom, the company collaborates with over sixty customers, including pharmaceutical and chemical companies, research institutions, and universities, to enhance the drug development process and chemical safety assessments.

Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

DC biosciences provides pharmaceutical and biotech companies with novel technologies and proteomics services to support the development of safer drugs faster. We are best placed to apply our knowledge and experience in a wide range of bioscience disciplines including quantitative proteomics, chemical biology, biochemistry, molecular biology, bioinformatics and cell biology to provide solutions in key areas of drug discovery and development.

Nandi Proteins Limited is a sales, marketing, IP and licensing company spun out of Heriot Watt University, Edinburgh in 2001. The company was established to exploit patented process technology and know how to improve the functional properties of common proteins such as whey, egg and soy. The company's objective is to become a market leader in the field of denatured protein technology and to deliver significant growth via direct trading of its value added proteins and a licensing approach with significant industry partners.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from waste streams in the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms and is suitable for a wide range of applications, including paints, coatings, paper, food products, personal care, home care, cosmetics, concrete, drilling fluids, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on creating sustainable, non-hydrocarbon-based materials that enhance product performance while also promoting cost savings for its clients.